 Dicerna Pharmaceuticals Inc NASDAQ: DRNA initiates patient dosing in Phase 1 PHYOX 4 trial evaluating its lead candidate, nedosiran, to treat primary hyperoxaluria, a rare condition characterized by the recurrent kidney and bladder stones. The condition often results in end-stage renal disease. 